Hospital
HH Health System - Athens Limestone, LLC
HH Health System - Athens Limestone, LLC was paid $2.74M by Medicaid between Jan 2018 and Dec 2024, across 94 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoHH HEALTH SYSTEM - ATHENS LIMESTONE, LLC
ATHENS, AL 35611
ATHENS, AL 35611
33aNPI1144695081assigned 12/03/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.74M
24GClaims172,107
24DCodes billed94
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#27 of 77
Median peer was paid$1.13M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,496 | $426K | |
| 2019 | 34,911 | $436K | |
| 2020 | 21,834 | $299K | |
| 2021 | 21,882 | $305K | |
| 2022 | 23,420 | $333K | |
| 2023 | 23,403 | $544K | |
| 2024incomplete | 13,161 | $393K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 16,795 | 13,599 | $928K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 18,947 | 15,774 | $579K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 15% | 12,947 | 10,985 | $420K |
| 80053 | Comprehensive metabolic panel | 6.5% | 21,774 | 17,441 | $178K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.4% | 22,432 | 17,873 | $148K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.1% | 1,582 | 1,134 | $59K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 5,280 | 4,190 | $40K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.4% | 2,764 | 2,452 | $38K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 726 | 682 | $36K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 4,810 | 2,457 | $35K |
| 81003 | 1.3% | 16,863 | 13,457 | $35K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 521 | 430 | $32K |
82 more codes
| 87070 | 1.1% | 2,902 | $29K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,813 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 372 | $15K |
| 84703 | <1% | 2,690 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,387 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 365 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,252 | $10K |
| 84484 | <1% | 1,796 | $9K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 170 | $9K |
| 83690 | <1% | 1,391 | $7K | |
| 80306 | <1% | 645 | $6K | |
| 30140 | <1% | 57 | $6K | |
| 85610 | <1% | 2,087 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 356 | $5K |
| 80061 | Lipid panel | <1% | 390 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 475 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 34 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 275 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 116 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 67 | $3K |
| 83880 | <1% | 196 | $3K | |
| 85730 | <1% | 2,085 | $3K | |
| 87420 | <1% | 186 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 254 | $2K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 23 | $2K |
| 82947 | <1% | 696 | $2K | |
| 85027 | <1% | 415 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 211 | $1K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 17 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,699 | $1K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 48 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $897.92 |
| 82607 | <1% | 52 | $734.76 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 53 | $673.53 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $672.63 |
| 84439 | <1% | 98 | $635.67 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,167 | $622.22 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,457 | $603.33 |
| 86803 | <1% | 72 | $545.61 | |
| 82746 | <1% | 40 | $433.80 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 32 | $432.12 |
| 74022 | <1% | 26 | $405.92 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $404.96 |
| 83735 | <1% | 98 | $378.91 | |
| 87581 | <1% | 18 | $332.40 | |
| 87486 | <1% | 18 | $332.40 | |
| 87653 | <1% | 24 | $296.52 | |
| 87210 | <1% | 68 | $260.15 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 895 | $252.26 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 42 | $251.44 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,231 | $180.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 547 | $174.15 |
| 93017 | <1% | 15 | $168.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 270 | $153.64 |
| 82553 | <1% | 35 | $153.09 | |
| 83605 | <1% | 19 | $148.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 677 | $136.00 |
| 87040 | <1% | 17 | $111.21 | |
| 82550 | <1% | 37 | $105.60 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 32 | $103.53 |
| 86592 | <1% | 31 | $103.02 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,279 | $70.49 |
| 87015 | <1% | 24 | $60.60 | |
| 86140 | <1% | 28 | $58.87 | |
| 82043 | <1% | 17 | $40.40 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 183 | $29.15 |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,076 | $18.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 184 | $15.88 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 51 | $14.64 |
| J2704 | Injection, propofol, 10 mg | <1% | 696 | $3.50 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 26 | $2.86 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 33 | $2.49 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $0.02 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 1,395 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | 0% | 187 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 17 | $0.00 |
| A9270 | Non-covered item or service | 0% | 605 | $0.00 |
| 94760 | 0% | 157 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 36 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOMER, JAMES (CHIEF FINANICAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Athens-Limestone Er Physicians | Athens, AL | $1.74M |
| Athens Limestone Health Services, LLC | Athens, AL | $1.25M |
| Athens Limestone Health Services LLC | Athens, AL | $106K |
| Health Care Authority of Athens and Limestone County | Athens, AL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.